scholarly journals Serum Hepcidin Level as a Marker of Iron Status in Children with Cystic Fibrosis

2018 ◽  
Vol 2018 ◽  
pp. 1-8
Author(s):  
Monika Kałużna-Czyż ◽  
Urszula Grzybowska-Chlebowczyk ◽  
Halina Woś ◽  
Sabina Więcek
Keyword(s):  
Cystic Fibrosis ◽  
Iron Status ◽  
Full Blood Count ◽  
Control Group ◽  
Hepcidin Level ◽  
Significant Difference ◽  
Serum Hepcidin ◽  
Liver Markers ◽  
Group Control Group ◽  
Active Inflammation

Introduction. Iron deficiency is common in patients with cystic fibrosis. Conventional iron status markers are often abnormal in patients with CF, reflecting inflammation and/or infection, rather than actual iron stores. The aim was to evaluate serum hepcidin levels against selected iron status markers, assuming that hepcidin may be a more sensitive indicator of iron management in patients with active inflammation, such as those with CF. Material and Methods. 46 children with cystic fibrosis and 31 healthy controls were enrolled. Hepcidin concentration was evaluated, along with the following other blood assays: full blood count, Fe, ferritin, transferrin, TIBC, liver markers, and CRP. Results. Higher ferritin and CRP levels as well as lower TIBC levels significantly predicted hepcidin levels in the study group, control group, and the entire sample. There was no significant difference in hepcidin levels between the patients and controls. Children with exacerbations had significantly higher hepcidin levels than those with stable disease. These findings support the serum hepcidin level as useful in assessing iron status in children with cystic fibrosis. It may also be useful in early detection and monitoring of treatment of exacerbations.

scholarly journals THE ASSOCIATION BETWEEN LEVELS OF HEPCIDIN, IRON STATUS AND MICRO-INFLAMMATION MARKERS AMONG HAEMODIALYSIS

2019 ◽  
Author(s):  
Ebtesam Ahmad Mufadhal ◽  
Fairouz Kaid Al-Showafi ◽  
Hassan A. Al-Shamahy ◽  
Ebtesam Mhdi Al-zabidi
Keyword(s):  
Peer Review ◽  
Serum Iron ◽  
Iron Status ◽  
Control Group ◽  
Inflammation Markers ◽  
C Reactive Protein ◽  
Maintenance Haemodialysis ◽  
Reactive Protein ◽  
Serum Hepcidin ◽  
E Mail

Hepcidin is a polypeptide that regulates iron homeostasis and could serve as an indicator of functional iron deficiency in patients with end-stage renal disease (ESRD); this may also aid in the assessment of patient's response to erythropoietin (EPO). Erythropoietin is a cytokine glycoprotein secreted by the kidney in response to cellular hypoxia; it stimulates the production of red blood cells (erythrocytes) in the bone marrow. The present study was aimed to investigate serum levels of hepcidin, iron status and inflammation markers such as C-reactive protein (CRP) in patients with ESRD on maintenance HD and to observe the correlation of serum hepcidin with conventional iron and inflammatory markers. A total of 59 patients on maintenance HD were enrolled; 29 age and sex-matched healthy subjects were included as controls. Laboratory tests including complete blood count, creatinine, urea, albumin, BUN, serum hepcidin, serum ferritin, serum iron and CRP were performed. The serum hepcidin levels was measured by a competitive enzyme-linked immunosorbent assay (C-ELISA). Serum hepcidin levels were significantly higher in patients with ESRD than in the control group (63.7±47.4 ng/mL: 11.5± 26.3 ng/mL respectively P<0.001). The hemoglobin and serum iron levels in the patient group were significantly lower than in the control group. Higher feritine levels were found in hemodialysis patients (448.5±710 ng/mL): ( 98.3±83 ng/mL) of controls (P =0.01). A positive and significant correlation was observed between the values of serum hepcidin and CRP.  Serum hepcidin and high-sensitivity C-reactive protein levels were significantly higher in maintenance haemodialysis patients (case=21.2±28.6 mg/L:control=2.9±2.7 mg/L, P=0.001). In conclusion, higher hepcidin levels are found in ESRD patients and serum hepcidin levels are associated with iron status and micro-inflammation (defined as hsCRP < 6mg/l, in maintenance haemodialysis patients). Also, our findings suggest that hepcidin might play a role in the pathophysiology of anemia associated with chronic diseases as ESRD. As well as, ELISA method for measuring serum hepcidin should facilitate the routine measurement of hepcidin in clinical practice. Peer Review History: UJPR follows the most transparent and toughest ‘Advanced OPEN peer review’ system. The identity of the authors and, reviewers will be known to each other. This transparent process will help to eradicate any possible malicious/purposeful interference by any person (publishing staff, reviewer, editor, author, etc) during peer review. As a result of this unique system, all reviewers will get their due recognition and respect, once their names are published in the papers. We expect that, by publishing peer review reports with published papers, will be helpful to many authors for drafting their article according to the specifications. Auhors will remove any error of their article and they will improve their article(s) according to the previous reports displayed with published article(s). The main purpose of it is ‘to improve the quality of a candidate manuscript’. Our reviewers check the ‘strength and weakness of a manuscript honestly’. There will increase in the perfection, and transparency. Received file Average Peer review marks at initial stage: 5.5/10 Average Peer review marks at publication st0ge: 8.5/10 Reviewer(s) detail: Name: Hebatallah Ahmed Mohamed Moustafa Affiliation: Heliopolis University Cairo, Egypt E-mail: [email protected]   Name: Dr. Heba M. Abd El-Azim  Affiliation: Damanhour University, Egypt E-mail: [email protected] Comments of reviewer(s):

Role of hepcidin as a biomarker for iron status and its effect on anemia management in patients with chronic kidney disease (stage II-Iv) after HCV treatment

QJM ◽  
2021 ◽  
Vol 114 (Supplement_1) ◽  
Author(s):  
Magdy M El Sharkawy ◽  
Lina E Khedr ◽  
Ashraf H Abdelmbdy ◽  
Mohamed T Mohamed
Keyword(s):  
Chronic Kidney Disease ◽  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Kidney Disease ◽  
Iron Status ◽  
Disease Stage ◽  
Hepcidin Level ◽  
Stage 4 ◽  
Ckd Stage ◽  
Serum Hepcidin

Abstract Background Anemia is a severe complication of chronic kidney disease (CKD) that is seen in more than 80% of patients with impaired renal function. Although there are many mechanisms involved in the pathogenesis of anemia of renal disease, the primary cause is the inadequate production of erythropoietin by the damaged kidneys. Aim of the work to assess hepcidin level in non dialysis patients (CKD stage 4 &5) treated from Hepatitis C virus and its relation to iron parameters. Patients and Methods This study was conducted on 20 CKD patients (stage 4 and 5) treated from hepatitis C virus. All candidates included in this study subjected to careful history taking, full clinical examination and investigations (including complete blood count, renal chemistry, HCVAb, serum iron, total iron binding capacity, TSAT%, ferritin and hsCRP. Serum hepcidin was analyzed by ELISA technique. Results Serum hepcidin was 26.35±7.26; 40% in stage III, 37.8% in stage IV and 22.2% in stage V. There was statistically significant difference between GFR stages according to Hb., Drug intake ACE inhibitor/ARB, Plt., Creatinine, BUN, Iron, TIBC, Ferritin, T SAT%, CRP and Serum Hepcidin. We showed significant correlations between serum hepcidin and TIC, Iron, TIBC, Ferritin and TSAT%. Conclusion Median hepcidin value is elevated in nondialysis CKD patients due to increased inflammation and decreased clearance of hepcidin. Furthermore, iron status modifies serum hepcidin level and its association with Hb. Increased hepcidin level leads to iron-restricted erythropoiesis and recombinant human EPO (rhEPO) resistance by inhibiting iron absorption from gut and iron recycling from macrophages. Hence, elevated hepcidin can predict need for parenteral iron to overcome hepcidin-mediated iron-restricted erythropoiesis and need for relatively higher rhEPO doses to suppress hepcidin.

scholarly journals Serum hepcidin and iron status parameters in pregnant women and the association with adverse maternal and fetal outcomes: a study protocol for a prospective cohort study

BMJ Open ◽  
2019 ◽  
Vol 9 (11) ◽  
pp. e032280
Author(s):  
Gabriela Amstad Bencaiova ◽  
Deborah Ruth Vogt ◽  
Irene Hoesli
Keyword(s):  
Cohort Study ◽  
Pregnant Women ◽  
Prospective Cohort Study ◽  
Prospective Cohort ◽  
Gestational Hypertension ◽  
Smoking Status ◽  
Iron Status ◽  
Neonatal Outcomes ◽  
Control Group ◽  
Serum Hepcidin

IntroductionHepcidin production is normally upregulated by iron stores, and in obesity has been shown to be overexpressed and correlated with low iron status. The increased hepcidin may restrain the iron release from the cells by affecting the expression of ferroportin, which probably associates with the development of diabetes complication. First, we investigate the difference of serum hepcidin and iron parameters between obese and non-obese pregnant women; second, we examine the correlation between serum hepcidin and adverse maternal and neonatal outcomes in pregnant women.Methods and analysisThis is a mono-centre, prospective cohort study with a study (obese) and a control group (non-obese women). In the first trimester, 188 singleton pregnancies will be recruited. Thereof, we expect 75 with a body mass index (BMI) ≥30 kg/m2and 113 with a BMI 18.5–30 kg/m2. Serum hepcidin, iron and haematological parameters will be measured at 11–14, 24–28, 32–36 weeks of gestation and at time of delivery. Blood pressure, weight, BMI and smoking status will be examined at all visits. We will assess the composite endpoints adverse maternal outcomes (including pre-eclampsia, gestational hypertension, gestational diabetes mellitus, haemorrhage, placenta abruption) and adverse neonatal outcomes (preterm birth, intrauterine growth restriction, preterm premature rupture of membranes, Apgar score <7 at 5 min, stillbirth, neonatal death).Recruitment has started in April 2019.Ethics and disseminationThis study received ethical approval from the ethics committee in Basel. The results of the study will be published in a peer-reviewed journal, and presented at national scientific conferences.Trial registration numberNCT03792464.

scholarly journals The Effect of Kelulut Honey on Fasting Blood Glucose and Metabolic Parameters in Patients with Impaired Fasting Glucose

2019 ◽  
Vol 2019 ◽  
pp. 1-7 ◽  
Author(s):  
Mohd Radzniwan Rashid ◽  
Khairun Nain Nor Aripin ◽  
Fathima Begum Syed Mohideen ◽  
Nizam Baharom ◽  
Khairani Omar ◽  
...  
Keyword(s):  
Impaired Fasting Glucose ◽  
Fasting Glucose ◽  
Low Density Lipoprotein ◽  
Fasting Blood Glucose ◽  
Daily Intake ◽  
Density Lipoprotein ◽  
Metabolic Parameters ◽  
Control Group ◽  
Significant Difference ◽  
Group Control Group

Background. Impaired fasting glucose (IFG) poses a higher risk of diabetes. Honey has been reported to improve metabolic abnormalities including lowering hyperglycemia. This study is sought at determining the effect of Malaysian Kelulut honey (KH) on fasting glucose levels and metabolic parameters in IFG patients. Methods. This quasi-experimental intervention study of 30-day duration was conducted among 60 adult patients with IFG. They were allocated into taking 30 g/day KH group (experimental group, n=30) and not taking KH group (control group, n=30). Body mass index (BMI), waist circumference, blood pressure (BP), fasting glucose, and lipid profile levels (total cholesterol, triglyceride, high-density lipoprotein, and low-density lipoprotein) were measured before and after treatment. Results. There was no significant difference in all measured variables at day 30 compared to day 1 within both groups. Similarly, all measured variables neither at day 1 nor at day 30 had shown a statistically significant difference between the groups. Conclusions. Daily intake of 30 g KH for 30 days resulted in insignificant effect on fasting glucose, fasting lipid profiles, and other metabolic parameters in patients with IFG. Further studies that employ longer study duration are needed to ascertain the finding.

scholarly journals Acute Effects of Static and Dynamic Stretching on Jump Performance of Volleyball Players

2021 ◽  
Vol 4 (3) ◽  
Author(s):  
Yasemin Arı ◽  
◽  
Ozan Sever ◽  
Aslıhan Arslangörür ◽  
Asım Tunçel ◽  
...  
Keyword(s):  
Rank Test ◽  
Control Group ◽  
Static Stretching ◽  
Acute Effects ◽  
Jump Performance ◽  
Dynamic Stretching ◽  
Friedman Analysis ◽  
Significant Difference ◽  
Volleyball Players ◽  
Group Control Group

The aim of this study is to examine the acute effects of different stretching methods on jump performance of volleyball players. 11 female volleyball players (age: 24.36 ± 5.10 years; height: 177.81 ± 7.30 cm; weight: 68.17 ± 11.69 kg; body mass index (BMI): 21.46 ± 2.56 kg.m-2; sports age: 12.72 ± 5.31 years) have participated voluntarily in this study. The players have applied three different stretching protocols such as control (no stretching), static and dynamic stretching on non-consecutive days. The protocols have included 5 minutes general warm-up, 1 minute rest, 30-second stretch program for each muscle group (control group not included), 1 minute rest and countermovement jump (CMJ), squat jump (SJ) and standing long jump (SLJ) tests. Friedman analysis has been used for data analysis. Wilcoxon Signed Rank Test has been implemented in order to determine the difference among groups. At the end of the study, a significant difference has been found between control and dynamic stretching groups with regard to static stretching groups in view of CMJ and SJ performance findings (p <0.05). It has been found that there is a statistically significant difference in the test averages of dynamic stretching group compared to static stretching group in view of SLJ performance findings (p <0.05). This study shows that static stretching practices reduce the jumping performance of the players. As a result, it can be suggested that trainers should use dynamic stretching methods before the trainings on jumping properties containing explosive movements.

scholarly journals Pengaruh suplementasi tablet fe mingguan dan harian terhadap kepatuhan minum tablet Fe dan perubahan kadar hemoglobin pada ibu hamil di Kabupaten Bantul Yogyakarta

2005 ◽  
Vol 2 (2) ◽  
pp. 45
Author(s):  
Dwi Susetyo ◽  
Mohammad Hakimi ◽  
Hamam Hadi
Keyword(s):  
Pregnant Women ◽  
Iron Status ◽  
Multiple Logistic Regression Analysis ◽  
Hemoglobin Level ◽  
Deficiency Anemia ◽  
Control Group ◽  
Folate Supplementation ◽  
Control Group Design ◽  
Significant Difference ◽  
Weekly Group

Background: In Indonesia, in 1995, 50.9% pregnant women suffer from Iron Deficiency Anemia (IDA).Objective: To compare the effect of weekly iron/folate vs standard daily iron/folate supplementation in pregnant women on compliance and hemoglobin level.Methods: The study was a quasi-experimental, non-equivalent control group design. Pregnant women with 20-28 week gestation were enrolled in this study in Bantul District. They were divided into two groups. One group (n=70), in Pajangan and Sewon Sub District, was given 120 mg iron/0,50 mg folate once a week, and the second group (n=65), in Bambang Lipuro and Pundong Sub District, received 60 mg iron/0,25 mg folate per day. Compliance with supplementation was assessed by the women self-reporting, pill count, and stool test. To measure hemoglobin level, the cyanmethemoglobin method was conducted.Results: Compliance was significantly higher in the weekly group (84.69% compared with 71.94%, p=0,004). A multiple logistic regression analysis indicated odds ratio 6.605, it means that in the weekly group compliance was 6,6 times higher than in the daily group. Hemoglobin level increased in both groups. There was no significant difference between groups for changes in hemoglobin. Initial haemoglobin values for the weekly (m=11.61 g/dl) and daily (m=11.27 g/dl) groups as well as final hemoglobin values (11.99 g/dl and 11.83 g/dl, respectively) did not differ significantly between the two groups.Conclusion: Supplementation on a weekly basis is as effective as daily supplementation in improving iron status in pregnant women. In the weekly group, compliance can be ensured.

scholarly journals Analysis of Bone Metabolism in Children with Cystic Fibrosis

PRILOZI ◽  
2018 ◽  
Vol 39 (1) ◽  
pp. 151-155
Author(s):  
Tatjana Jakovska
Keyword(s):  
Cystic Fibrosis ◽  
Bone Formation ◽  
Bone Markers ◽  
Formation Rate ◽  
Serum Markers ◽  
Control Group ◽  
Healthy Children ◽  
Pediatric Clinic ◽  
Significant Difference ◽  
The University

Abstract One of the most important CF-related conditions is the bone disease, which is nowadays acknowledged as a significant clinical complication of CF. Imbalance between bone formation and degradation in cystic fibrosis (CF) has become an important issue for developing osteopenia. The aim of the study was to assess bone formation and resorption process with bone markers in children with cystic fibrosis (CF). Materials and methods: The study included 35 clinically stable children with CF who regularly attended the Cystic fibrosis center at the University Pediatric Clinic in Skopje, R. Macedonia. The control group was presented with 21 healthy children at the same age. Serum osteocalcin (OC), β cross laps, 25OHD and PTH were determined by ELISA assays in the CF group (mean age 8.25±SD1.9 y.) and in age-match controls (7.5±1.9 y.). Results: Vitamin D in the CF group was (23.83±10.9 ng/ml versus 25.6±11.53 in the control group, p=0.57), OC (70.88±34.24 ng/ml v.100.02±47.98, p=0.01) βcrosslaps (1.35±0.72 ng/ml v.1.54±0.73, p=0.37) and PTH (37.39±25.5 pg/ml v. 36.76±25.73, p=0.92). In the study, we did not find a significant difference for 25OHD between CF and healthy controls. OC in children with CF correlates significantly with the control and indicates a decreased formation rate whereas resorption rate is normal. Conclusion: Our results suggest that bone turnover in CF is impaired in childhood. Serum markers for bone formation can be used for predicting osteopenia in children with CF.

scholarly journals Iron Homeostasis in Patients with Nonalcoholic Fatty Liver Disease

2021 ◽  
Vol 08 (02) ◽  
pp. 6-10
Author(s):  
Kuldeep Kumar ◽  
Keyword(s):  
Metabolic Syndrome ◽  
Liver Disease ◽  
Fatty Liver ◽  
Serum Ferritin ◽  
Fatty Liver Disease ◽  
Iron Status ◽  
Positive Association ◽  
Control Group ◽  
Significant Positive Association ◽  
Serum Hepcidin

Introduction: Serum ferritin correlates with hepatic iron deposition in patients with Non Alcoholic Fatty Liver Disease (NAFLD). Iron removal improves insulin sensitivity thereby delaying the onset of type 2 diabetes mellitus, improves liver function and NAFLD histology. Objectives: This study was done to assess the iron status in NAFLD patients and its association with fibrosis and metabolic syndrome in NAFLD. Material and Method: The study was conducted in the Department of Medicine, GTB Hospital, Delhi from November 2017 - October 2019. It was an Analytical, comparative study. Forty patients with NAFLD were selected in the study group and forty healthy subjects with no evidence of fatty liver on ultrasound were selected in the control group. The level of iron parameters recorded in NAFLD patients and the control group were compared using independent t test and p value of <0.05 was considered statistically significant. Assessment of association of various parameters of iron status with the presence of Metabolic Syndrome and fibrosis in NAFLD patients was done using the Chi-Square test. Result: The parameters of iron status namely serum iron, serum ferritin, transferrin saturation and serum hepcidin were found to be higher in NAFLD patients when compared to controls. This study also observed that there was a statistically significant positive association of serum ferritin with the presence of MetS in NAFLD patients. The study also found that serum hepcidin and serum ferritin have a significant positive association with fibrosis in NAFLD. Discussion: Assessment of iron status in NAFLD may help in early identification of individuals at high risk of fibrosis and other complications like Mets. Application of iron removal strategies like phlebotomy in such patients might improve IR and NAFLD.

scholarly journals Adult Patients Affected by Cystic Fibrosis in Therapy with Cystic Fibrosis Transmembrane Regulator Modulators and Lung Transplant: Renal Function, Metabolic and Nutritional Status

2020 ◽  
Vol 2020 ◽  
pp. 1-8
Author(s):  
Silvia Lai ◽  
Sandro Mazzaferro ◽  
Anna Paola Mitterhofer ◽  
Francesca Tinti ◽  
Enea Bonci ◽  
...  
Keyword(s):  
Cystic Fibrosis ◽  
Renal Function ◽  
Nutritional Status ◽  
Lung Transplant ◽  
Conservative Therapy ◽  
Control Group ◽  
Inflammatory Status ◽  
Significant Difference ◽  
Cystic Fibrosis Transmembrane ◽  
Cftr Modulators

Background. Cystic fibrosis (CF) is one of the most frequent genetic diseases. The discovery and implementation of new therapies prolonged the survival of CF patients in the last years. Evaluation of long-term complications could be useful to improve the outcome of these patients. Aim of the Study. To evaluate renal function, metabolic, nutritional, and inflammatory status in CF patients on cystic fibrosis transmembrane regulator (CFTR) modulators therapy as well as lung transplant recipients (LRs) and patients on conservative therapy (control group). Materials and Methods. We performed a prospective, longitudinal study on 69 CF patients. Clinical and laboratory parameters (metabolic and nutritional indices and inflammatory markers) were evaluated in all patients before starting CFTR therapy or transplant (T0) and after 3 years (T1). Results. We enrolled 69 CF patients (42 males). Patients were distributed into three groups. The average age was 35.01 ± 10.57 years for the control group (group 0), 32.47 ± 9.40 years for patients on CFTR modulators therapy (group 1), and 38.93 ± 7.14 years for LRs (group 2). At T1, we showed a significant difference among the three groups in terms of renal function indices: creatinine, eGFR, serum nitrogen as well as serum uric acid, sodium, and potassium ( p < 0.001 , p < 0.001 , p < 0.001 , p < 0.001 , p < 0.001 , and p < 0.001 , respectively), particularly in LRs patients. Significant differences were found in nutritional status parameters among the three groups: total protein, serum albumin, serum fibrinogen, serum transferrin, and white blood cell counts ( p < 0.001 , p = 0.037 , p = 0.04 , p = 0.003 , and p = 0.007 , respectively), particularly in LRs compared with other groups. Moreover, we found significant differences in metabolic profile (HbA1c, p = 0.026 ) and inflammatory status, with a significant difference in C-reactive protein values, neutrophil counts, and neutrophil-lymphocyte ratio (NLR) among the three groups ( p < 0.001 , p = 0.005 , and p = 0.026 , respectively). Conclusions. Our study showed a reduced renal function and poor nutritional status in LRs, along with worse metabolic control. Moreover, we showed a lower inflammatory status in patients on CFTR modulators therapy. Therefore, we suggest early and careful monitoring of renal function, metabolic, and nutritional parameters in CF patients, whether they are on conservative therapy, CFTR modulators therapy, and LRs patients.

Sign in / Sign up

Export Citation Format

Share Document